Clinical Trial

Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors

Name: Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors — clinical trial record (NCT07349160)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

A Study of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) Therapy for Patients With Advanced Solid Tumors

Trial Details

NCT Number	NCT07349160
Lead Sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences Collaborators: Leman Biotech Co., Ltd.
Conditions	Advanced Solid Tumors
Enrollment	36 participants
Start Date	2026-01-10
Primary Completion	2027-03-15 (estimated)
Study Completion	2028-01-20 (estimated)
Updated on ClinicalTrials.gov	2026-01-16